EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular disease and infectious diseases, has announced today it has signed a memorandum of understanding with Spire Healthcare Group plc (LON:SPI), a leading independent healthcare group in the UK.
Under the terms of the memorandum of understanding, EDX Medical and Spire Healthcare will explore opportunities to utilise new diagnostic products and patient testing services. This will include:
· Promoting each other’s existing and future clinical products and services.
- Establishing innovative patient referral and treatment pathways with the objective of cost-effectively improving patient outcomes.
- Developing joint healthcare and wellbeing propositions based on improved understanding of patient biology, disease risk and personalised treatments.
· Providing services to support the delivery of world class independent healthcare in the United Kingdom.
Professor Sir Chris Evans, founder and chief scientific officer of EDX Medical, commented: “Spire Healthcare is an outstanding healthcare leader and we at EDX Medical are delighted to sign this agreement which paves the way for us to work together to further improve the delivery of innovative diagnostics and class-leading personalised medicine for patients. Relationships with leading hospital groups and clinics are an important element of our strategy to develop and supply the most advanced tests and supporting services available to treat major diseases.”
Dr Mike Hudson, CEO, EDX Medical, commented: “We are excited to enter this new initiative with Spire Healthcare which promises to unlock important benefits for Spire’s patients by providing their doctors with early access to advanced clinical diagnostic tools, enabling the delivery of world class personalised medicine.”
Justin Ash, CEO, Spire Healthcare, said: “We have developed an excellent relationship with EDX Medical and are delighted to collaborate more closely to offer first option on and early access to new, innovative diagnostic products and patient testing services. Working in partnership will enable us to offer more personalised prevention support, treatment and care for people across a range of cancers, cardiovascular and other conditions.”
